TY - JOUR A1 - Schneider, Rudolf A1 - Carvalho, A. M. A1 - Manicardi, A. A1 - Montes, C. V. A1 - Gunnoo, S. B. A1 - Madder, A. T1 - Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization N2 - Trastuzumab (Herceptin) is an FDA-approved therapeutic antibody currently employed in the treatment of metastatic stages of breast cancer. Herein, we propose a simple, fast and cost-effective methodology to conjugate trastuzumab with 22-mer 5' thiol-modified oligonucleotides using a bifunctional crosslinker. The conjugates were successfully characterized by MALDI-ToF MS and SDS-PAGE, obviating the need for enzymatic digestion and difficult chromatographic separations. Furthermore, ELISA was performed to ensure that trastuzumab activity is not affected by oligonucleotide conjugation. KW - MALDI-ToF KW - ELISA PY - 2017 U6 - https://doi.org/10.1039/c7ob02216f SN - 1477-0539 VL - 15 IS - 42 SP - 8923 EP - 8928 AN - OPUS4-43328 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -